Physician profile
Bruce W Young
NPI 1487641866
$2,756.09
in general payments reported to CMS, 2019-2025
21 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $64.69 · 2021: $288 · 2022: $445 · 2023: $744 · 2024: $671 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $665.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $364.03 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $357.72 | 2019-2025 | Vraylar |
| Glaxosmithkline, LLC. | $293.34 | 2021-2024 | Arexvy, Shingrix |
| Pfizer INC. | $231.01 | 2019-2025 | |
| Genzyme Corporation | $185.00 | 2019 | |
| Amgen INC. | $124.41 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.95 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $103.63 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boston Scientific Corporation | $70.40 | 2023-2024 | Rotapro, Synergy |
| Noven Therapeutics, LLC | $55.12 | 2023-2024 | Xelstrym |
| Sanofi-Aventis U.S. LLC | $50.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.15 | 2023-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $17.45 | 2023 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.33 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $17.16 | 2024 | Qelbree |
| Novartis Pharmaceuticals Corporation | $15.90 | 2019 | |
| Amarin Pharma, INC. | $15.14 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.58 | 2019 | |
| Zyla Life Sciences, INC. | $13.27 | 2019 | |
| Merck Sharp & Dohme LLC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.